Summit Therapeutics Inc. (SMMT): Earnings growth forecast for next year

Summit Therapeutics Inc (SMMT) - corporate logo

Summit Therapeutics is engaged in patent battles within the harsh oncology environment, strictly adhering to environmental regulations regarding chemical disposal. Analyst valuations of net profit dynamics for n+1 demonstrate the result of these efforts, where the 3.80 mark indicates the level of current expectations. The future success of the business depends on FDA approval of drugs for lung cancer therapy.

SMMT - Summit Therapeutics plc Projected earnings per share increase next year over the range 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for summittxinc.com (SMMT)

- share price and consensus valuation forecast:
Stock Price Summit Therapeutics Inc|SMMT - Average Forecast Price
- stock exchange capitalization data:
Market Capitalization Summit Therapeutics|SMMT - Real Price to Acquire Entire Company
- book capitalization indicators:
Accounting Value per Share Summit Therapeutics|SMMT - Total Net Assets|Market Capitalization to Book Value Ratio summittxinc.com|SMMT - Company Total Asset Base
- company liabilities and liquidity data:
Debt to Equity Summit Therapeutics|SMMT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Summit Therapeutics Inc.|SMMT - Company Aggregate Debt|Debt to Book Capitalization Ratio Summit Therapeutics|SMMT - Long-Term Debt Volume|Company Short-Term Debt Summit Therapeutics|Quick Liquidity Indicator summittxinc.com
- earnings and market ratios statistics:
SMMT - Net Profit|Expected Profit Summit Therapeutics|SMMT - Price to Earnings Ratio|Future Price to Earnings Summit Therapeutics|SMMT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Summit Therapeutics|SMMT - Operating income before deduction of amortization|Net earnings per share for the last 12 months Summit Therapeutics|SMMT - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months summittxinc.com|SMMT - Earnings per share increase in current year|Expected earnings per share growth for next year Summit Therapeutics
General company analysis:SMMT, Summit Therapeutics Inc
Core merchandise of Summit Therapeutics Inc.

Institutional capital assesses the attractiveness of Summit Therapeutics (SMMT) through the lens of future profitability. This projected earnings per share (EPS) for the coming year aggregates daily updated analyst consensus forecasts regarding net income dynamics. For a company with the unique ivonescab, such a metric reflects the monetization of pricing power within the inelastic oncology therapy market. The steady growth of this indicator confirms the asset's fundamental stability and justifies the current share price.

Competitor analysis

MRNA (Moderna Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year SutroVax PCVX|Earnings growth forecast for next year TARS|Expected earnings per share growth for next year cormedix.com CRMD|Seres Therapeutics, Inc. - Expected earnings per share growth for next year|Projected earnings per share increase next year SPRO (Spero Therapeutics Inc)|Scynexis - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year AN2 Therapeutics, Inc. ANTX|polypid.com (PYPD) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year ysbiopharm.com (LSB)|Net earnings per share growth forecast for next year Iterum Therapeutics PLC|Projected earnings per share growth rate for next year PHGE (BiomX Ltd)|Net earnings per share growth forecast for next year Soligenix, Inc. (SNGX)|Consensus forecast of earnings per share growth for next year 60degreespharma.com|Net earnings per share growth forecast for next year Oragenics OGEN|Consensus forecast of earnings per share growth for next year opgen.com (OPGN)